Campbell Soup stock gains ground after profit matches expectations while sales top, as prices jump 10%
Shares of Campbell Soup Co. (CPB) tacked on 0.9% in premarket trading Thursday, after the canned soup, foods and snacks company reported fiscal fourth-quarter profit that matched expectation and sales that topped, as a 10% increase in prices offset a 5% decline in volume and mix. Net income for the quarter to July 30 rose to $169 million, or 57 cents a share, from $96 million, or 32 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 50 cents was the same as the FactSet consensus. Sales grew 4.1% to $2.068 billion, above the FactSet consensus of $2.056 billion, as meals and beverages sales inched up 0.1% to $936 million and snacks sales increased 7.6% to $1.13 billion. Price increased 6% in meals and beverages and rose 13% in snacks, while volume fell 5% in both segments. For fiscal 2024, the company expects adjusted EPS of $3.09 to $3.15, compared with the FactSet consensus of $3.09, and sees sales growth of negative 5% to positive 1.5% while the current FactSet sales consensus of $9.47 billion implies 1.2% growth. The stock has tumbled 17% over the past three months through Wednesday while the S&P 500 has gained 8%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-31-23 0735ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks